Yes—absolutely.
In fact, regulatory strategy is most powerful before a physical prototype exists.

At the earliest stage, regulatory thinking acts as a design compass. It tells you what you can build, how risky it will be, and what proof you’ll eventually need—before you spend real money on engineering.

How Regulatory Strategy Works at the “Paper Stage”

Even without a prototype, regulatory strategy can shape three critical pillars of development.

1. Defining Design Inputs Before Design Begins

Regulatory strategy helps translate a raw idea into regulatory-ready design inputs, including:

Intended use and indications for use

User population and use environment

Safety-critical functions

Performance expectations tied to risk

These inputs form the foundation of FDA design controls. When they are defined early, engineering efforts stay aligned with regulatory expectations instead of drifting into redesign territory.

From the perspective of the U.S. Food and Drug Administration, design controls are not optional—they are the backbone of device development.

2. Early Risk Classification Without Hardware

You do not need a prototype to perform meaningful risk analysis.

Using concept-level information, regulatory strategy can:

Estimate device classification (Class I, II, or III)

Identify primary hazards (biological, electrical, software, usability)

Anticipate testing categories such as biocompatibility, software validation, or human factors

This early risk framing prevents teams from unknowingly designing a high-risk device when a lower-risk approach would meet the same clinical need.

3. Evidence Planning Before Testing Exists

One of the biggest advantages of early regulatory strategy is evidence planning without waste.

At the paper stage, teams can:

Map risks to required bench, animal, or clinical evidence

Identify which standards and guidances will apply

Decide what data must be generated—and what can be avoided

This allows development programs to be built intentionally, not reactively.

Once testing starts, it is already too late to ask whether the data will count.

Why This Saves Time and Money

Early regulatory strategy:

Prevents unnecessary prototyping

Reduces the chance of forced regulatory pathway changes

Ensures early capital is spent on work that survives FDA review

For early-stage companies, this can mean the difference between reaching a regulatory milestone—or running out of runway.

Where Kandih Comes In

This is where Kandih Group adds the most value.

Kandih supports founders at the paper stage, before engineering costs escalate, by:

Pressure-testing ideas against FDA logic

Defining regulatory-ready intended use and design inputs

Conducting concept-level risk assessments

Outlining evidence strategies aligned with FDA expectations

Helping teams deploy capital efficiently and defensibly

Instead of guessing what FDA will want later, founders can design forward with confidence.

Bottom Line

You don’t need a prototype to start regulatory strategy.
You need regulatory strategy to know what prototype to build.

Starting early de-risks development, protects capital, and accelerates time to market.

That’s how Kandih helps innovators move faster—without breaking things later.

References

FDA – Design Controls for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices

FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device

FDA – ISO 14971: Risk Management for Medical Devices
https://www.fda.gov/medical-devices/standards-and-conformity-assessment-program/recognized-consensus-standards

FDA – Benefit-Risk Factors for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device